Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Jul 13, 2026
Goldman Sachs (GS): Can the Stock Reach $1,200?

Goldman Sachs (GS): Can the Stock Reach $1,200?

Key Takeaways

  • The Goldman Sachs Group, Inc. (GS) currently trades near $1,056, with a 52-week high of $1,125 set in June 2026.
  • A move to $1,200 would require a roughly 13.6% gain and a breakout above the all-time high, sitting just above the most bullish Wall Street target of $1,195 from Wells Fargo.
  • Record M&A advisory volume exceeding $1 trillion in the first half of 2026 and surging trading revenue from AI-related activity and the SpaceX IPO provide powerful fundamental tailwinds.
  • The analyst consensus remains a cautious Hold with an average price target near $1,010, while Oppenheimer recently downgraded the stock to Underperform on valuation concerns.
  • Clearing the $1,125 resistance level and delivering a strong Q2 earnings report on July 14 are essential steps before $1,200 becomes a realistic near-term objective.

Why the $1,200 Level Stands Out

The $1,200 price target has become a focal point for GS shareholders. It represents a clean, round-number milestone just above Wells Fargo analyst Mike Mayo’s $1,195 target and comfortably clear of the stock’s all-time high at $1,125. After more than 50% gains over the past year and roughly 235% over three years, the question of whether the stock can extend further is a logical one. Reaching that level would require both sustained momentum from the current dealmaking environment and a market willing to price in peak-cycle earnings at a premium.

Current Market Position

Shares of GS closed at $1,055.97 on July 9, 2026, up 2.56% that session. The stock sits about 6% below its 52-week high and has delivered a year-to-date gain of roughly 20%. With a market capitalization near $315 billion and a trailing P/E around 19.3, the valuation reflects both strong current earnings and some uncertainty about how long the favorable environment can last. Return on equity has moved toward 19% annualized, up from 15% in fiscal 2025, supported by growth in asset and wealth management alongside the cyclical lift in investment banking.

What Could Support a Move Toward $1,200

The case for higher prices rests on the durability of Goldman’s recent performance. The firm surpassed $1 trillion in announced M&A advisory volume in the first half of 2026—the quickest pace on record for any bank—with a 42% market share. That strength in high-margin advisory work is paired with robust equity trading revenue tied to AI-related activity and major IPOs such as SpaceX. Longer term, the firm is growing its fee-based asset and wealth management platform, with a goal of $750 billion in alternative assets under supervision by 2030. An 11% dividend increase announced in June underscores management’s confidence. If the July 14 earnings report tops already elevated expectations and points to continued pipeline strength, the stock could test record highs and build toward $1,200.

Key Obstacles to Consider

Several factors could limit upside. The immediate technical hurdle is the $1,125 all-time high, which has acted as resistance. More broadly, investment banking remains cyclical, and the current $1 trillion M&A pace may not be sustainable. Some sum-of-the-parts analyses place fair value near $732, suggesting the current price already prices in optimistic assumptions about sustainable ROE. The stock’s 7% weekly drop after OpenAI’s IPO delay highlighted sensitivity to any signs of a slowing pipeline. Macro risks, including the possibility of higher-for-longer rates dampening financing activity and increased regulatory focus on AI-related financing, add further caution.

Analyst Views and Price Targets

Wall Street remains divided. The consensus rating is a Hold, with an average 12-month target near $1,010—slightly below the current price. The range is wide, however. Wells Fargo’s Mike Mayo holds an Overweight rating and $1,195 target, while Bank of America recently lifted its target to $1,150. On the other side, JPMorgan is Neutral with a $900 target, and Oppenheimer’s Chris Kotowski downgraded the stock to Underperform on June 30, citing valuation even after raising earnings estimates. This split captures the central tension: fundamentals are strong, yet much of the positive news may already be reflected in the price.

Important Technical Levels

From a technical standpoint, $1,125 is the key resistance that must be cleared before $1,200 becomes realistic. It marks the June 2026 all-time high and the last barrier before price discovery in new territory. Support begins at the $1,000 psychological level and the 50-day moving average near $1,012. A sustained break above $1,125 on strong volume would indicate the uptrend is resuming and open the door to the $1,150–$1,200 area. A failure at the highs followed by a drop below $1,000 could point to a deeper consolidation phase. I also checked this using Tickeron’s AI Pattern Search Engine to see how current patterns align with historical breakouts.

Valuation Perspective

At roughly 19 times trailing earnings, GS trades below the capital markets industry average but above its own long-term historical multiple. The forward P/E near 15.9, based on next-year estimates of $66.42 per share, implies continued earnings growth. Valuation remains sensitive to the sustainability of peak returns. If ROE can hold near 19% and fee-based businesses keep expanding, a multiple expansion toward 20–22 times could support a move to $1,200. A reversion toward mid-cycle earnings would make the current valuation look stretched.

Using AI Daily Buy/Sell Signals for Context

Navigating a stock with as many cross-currents as Goldman Sachs requires timely and data-driven decision-making. Tickeron’s AI Daily Buy/Sell Signals provide traders with continuously updated Buy, Sell, or Hold signals generated by artificial intelligence that monitors thousands of stocks and ETFs in real time. The system analyzes changing market conditions, technical patterns, and AI-driven insights to help traders identify emerging opportunities, manage existing positions, and stay ahead of shifting trends. For a stock like GS, where the debate between cyclical peak and durable growth is finely balanced, having an objective, data-driven signal can help cut through the noise and support more confident decision-making.

Final Assessment

The $1,200 target is ambitious but plausible. It would require breaking above the all-time high, sustaining record dealmaking momentum, and convincing the market that peak-cycle earnings are more durable than some skeptics expect. The strongest supports are the firm’s dominant M&A market share, growth in fee-based wealth and asset management, and the potential for a strong Q2 earnings catalyst. The main risks remain the cyclical nature of investment banking, a valuation that already embeds optimistic assumptions, and the possibility that the deal pipeline moderates later in 2026. Investors should watch the July 14 earnings report closely, especially pipeline commentary, and track whether the stock can clear $1,125. Until those conditions are met, $1,200 remains a realistic but conditional objective rather than an imminent destination.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations
Related Ticker: GS

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


GS sees its Stochastic Oscillator recovers from oversold territory

On August 03, 2026, the Stochastic Oscillator for GS moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 53 instances where the indicator left the oversold zone. In of the 53 cases the stock moved higher in the following days. This puts the odds of a move higher at over .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GS advanced for three days, in of 355 cases, the price rose further within the following month. The odds of a continued upward trend are .

GS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 287 cases where GS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for GS moved out of overbought territory on July 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 42 similar instances where the indicator moved out of overbought territory. In of the 42 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on July 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GS as a result. In of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for GS turned negative on July 23, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at .

GS moved below its 50-day moving average on August 06, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for GS crossed bearishly below the 50-day moving average on July 31, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. GS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.740) is normal, around the industry mean (4.148). P/E Ratio (15.945) is within average values for comparable stocks, (20.994). Projected Growth (PEG Ratio) (1.465) is also within normal values, averaging (1.663). Dividend Yield (0.016) settles around the average of (0.033) among similar stocks. P/S Ratio (4.838) is also within normal values, averaging (31.056).

Notable companies

The most notable companies in this group are Morgan Stanley (NYSE:MS), Goldman Sachs Group (NYSE:GS), Charles Schwab Corp (The) (NYSE:SCHW), Gold.com Inc. (NYSE:GOLD).

Industry description

These banks specialize in underwriting (helping companies with debt financing or equity issuances), IPOs, facilitating mergers and other corporate reorganizations and acting as a broker or financial advisor for institutions. They might also trade securities on their own accounts. Investment banks potentially thrive on expanding its network of clients, since that could help them increase profits. Goldman Sachs, Morgan Stanley and CME Group Inc are some of the largest investment banking companies.

Market Cap

The average market capitalization across the Investment Banks/Brokers Industry is 13.14B. The market cap for tickers in the group ranges from 13 to 928.5B. PKRSF holds the highest valuation in this group at 928.5B. The lowest valued company is BFCH at 13.

High and low price notable news

The average weekly price growth across all stocks in the Investment Banks/Brokers Industry was -1%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was -14%. USDE experienced the highest price growth at 36%, while TOP experienced the biggest fall at -80%.

Volume

The average weekly volume growth across all stocks in the Investment Banks/Brokers Industry was -38%. For the same stocks of the Industry, the average monthly volume growth was -25% and the average quarterly volume growth was -69%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 63
P/E Growth Rating: 70
Price Growth Rating: 63
SMR Rating: 76
Profit Risk Rating: 86
Seasonality Score: -7 (-100 ... +100)
View a ticker or compare two or three
GS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a provider of investment banking, securities and asset management services

Industry InvestmentBanksBrokers

Profile
Details
Industry
Investment Banks Or Brokers
Address
200 West Street
Phone
+1 212 902-1000
Employees
45300
Web
https://www.goldmansachs.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.